News
 

A new study investigate about the dose-response of daridorexant, a new dual orexin receptor antagonist, on wake after sleep onset (WASO).

Neurologic effects can be a significant part of COVID-19, but does the SARS-CoV-2 virus directly damage the central nervous system or are the neurologic symptoms attributable to secondary mechanisms?

Air pollution may be another environmental risk factor for developing multiple sclerosis (MS), new research suggests.

The calcitonin gene-related peptide monoclonal antibody galcanezumab (Emgality, Lilly) compared favorably to placebo for reducing the number of average monthly migraine days in a new study of people with treatment-resistant migraine headaches.

Preclinical evidence with nilotinib, a US Food and Drug Administration (FDA)‐approved drug for leukemia, indicates improvement in Alzheimer's disease phenotypes.

Researchers are taking a closer look at whether the diabetes medication metformin might convey benefit in patients with both Parkinson's disease (PD) and diabetes - and are finding some positive signals.

This week we have received a new study about Parkinson and tobacco (DOI: https://doi.org/10.1212/WNL.0000000000009437)

Lowering blood pressure (BP) with antihypertensive agents is linked to a significant reduction in the risk of dementia or cognitive impairment, new research suggests.

Patients with the 'aggressive' form of multiple sclerosis accrue disability at an accelerated rate, typically reaching Expanded Disability Status Score (EDSS) ≥ 6 within 10 years of symptom onset. Several clinicodemographic factors have been associated with aggressive multiple sclerosis, but less research has focused on clinical markers that are...

Adults who develop amyotrophic lateral sclerosis (ALS) metabolize metals differently than those who do not develop the neurodegenerative disease, and this shows up in teeth during childhood, new research suggests.